{"id":"lanreotide-microparticles","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Diarrhea"},{"rate":"15-30","effect":"Abdominal pain"},{"rate":"10-25","effect":"Nausea"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"10-20","effect":"Steatorrhea"},{"rate":"5-15","effect":"Cholelithiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanreotide acts as a long-acting somatostatin receptor agonist, mimicking the inhibitory effects of endogenous somatostatin. The microparticle formulation provides sustained release of the active peptide, allowing for extended suppression of growth hormone, insulin-like growth factor-1 (IGF-1), and other neuroendocrine hormones. This mechanism is used to control symptoms and slow tumor growth in neuroendocrine tumors and acromegaly.","oneSentence":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:14.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors (gastroenteropancreatic and thoracic)"},{"name":"Carcinoid syndrome"}]},"trialDetails":[{"nctId":"NCT00216372","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2003-09","conditions":"Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms","enrollment":80},{"nctId":"NCT00729313","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae","status":"COMPLETED","sponsor":"Ipsen","startDate":"2000-04","conditions":"Digestive Fistulae","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lanreotide microparticles","genericName":"Lanreotide microparticles","companyName":"Ipsen","companyId":"ipsen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Neuroendocrine tumors (gastroenteropancreatic and thoracic), Carcinoid syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}